Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture of proteins applicable to a range of disease agents, such as influenza, sleeping sickness, anthrax, plague, human papillomavirus and veterinary influenza applications. IBio, Inc. is headquartered in Newark, Delaware.
| Revenue (Most Recent Fiscal Year) | $2.38M |
| Net Income (Most Recent Fiscal Year) | $-50.30M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.45 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.68 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -11133.67% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -150.09% |
| Return on Assets (Trailing 12 Months) | -79.33% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.22 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.22 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.04 |
| Inventory Turnover (Trailing 12 Months) | 0.22 |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.27 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.08 |
| Earnings per Share (Most Recent Fiscal Year) | $-5.78 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 16.80M |
| Free Float | 16.40M |
| Market Capitalization | $12.56M |
| Average Volume (Last 20 Days) | 0.19M |
| Beta (Past 60 Months) | -3.19 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.38% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |